Recombinant Human CDKN3 Protein，His

CDKN3, or Cyclin-dependent kinase inhibitor 3, is a pivotal protein involved in regulating the cell cycle by inhibiting cyclin-dependent kinases (CDKs). The dysregulation of CDKN3 has been associated with various cancers, making it a potential target for tumorigenesis research and therapeutic interventions. CDKN3 functions by controlling the transition from the G1 to S phase of the cell cycle, and its downregulation or mutation can lead to unchecked cellular proliferation, a hallmark of cancer. Studies have shown that alterations in CDKN3 expression levels can influence the sensitivity of cancer cells to various chemotherapeutic agents, underscoring its importance in cancer biology. Moreover, understanding the molecular mechanisms governing CDKN3's activity and interaction with other cell cycle regulators could provide novel insights into the development of targeted cancer therapies. Recent advances in recombinant protein technology have made it possible to produce CDKN3 in vitro, facilitating a more detailed investigation into its functional properties and potential as a therapeutic target. The exploration of CDKN3 in the context of cancer highlights its significance not only in cell proliferation control but also in the broader landscape of tumor biology and treatment strategies. As such, CDKN3 represents a compelling candidate for further research aimed at elucidating its role in oncogenesis and as a biomarker for cancer diagnosis and prognosis.